靶点- |
作用机制- |
|
|
在研适应症- |
|
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期- |
A Phase 1, Randomized, Double-blind, Crossover Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of QEV-817 Oral Suspension in Healthy Volunteers
This study has been designed to assess the safety, tolerability, and pharmacokinetics of a therapeutic dose of hydrocodone bitartrate with and without an oral dose of doxapram hydrochloride in healthy volunteers who are naltrexone-blocked.
100 项与 Quivive Pharma, Inc. 相关的临床结果
0 项与 Quivive Pharma, Inc. 相关的专利(医药)
100 项与 Quivive Pharma, Inc. 相关的药物交易
100 项与 Quivive Pharma, Inc. 相关的转化医学